Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Knight Therapeutics Inc.

Healthcare CA GUD

8.31CAD
0.11(1.34%)

Last update at 2026-06-03T20:00:00Z

Day Range

8.088.42
LowHigh

52 Week Range

5.507.74
LowHigh

Fundamentals

  • Previous Close 8.20
  • Market Cap736.73M
  • Volume46676
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA49.40M
  • Revenue TTM450.09M
  • Revenue Per Share TTM4.52
  • Gross Profit TTM 200.23M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.70200M 2.05M -21.98800M -43.96000M 6.69M
Minority interest - - - - -
Net income -5.37400M 4.33M -16.83500M -29.89200M 15.68M
Selling general administrative 124.11M 99.35M 37.41M 40.15M 37.16M
Selling and marketing expenses - - 46.28M 48.47M 37.22M
Gross profit 150.74M 174.41M 107.61M 138.06M 115.41M
Reconciled depreciation 56.57M - - - -
Ebit -2.20100M - 6.43M -2.40300M -5.32200M
Ebitda 54.37M - 56.82M 60.22M 42.59M
Depreciation and amortization 56.57M - 50.40M 62.62M 47.91M
Non operating income net other - - - - -
Operating income -2.20100M 7.40M 6.43M -2.40300M -5.32200M
Other operating expenses 452.29M - 321.77M 310.62M 256.31M
Interest expense 10.42M - 12.49M 6.60M 3.62M
Tax provision -1.32800M -2.28000M -5.15300M -14.06800M -
Interest income 6.21M 16.23M 28.50M 15.76M -
Net interest income -4.21600M - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.32800M - -5.15300M -14.06800M -8.98500M
Total revenue 450.09M 371.30M 328.20M 293.56M 243.48M
Total operating expenses 152.94M - 101.19M 155.12M 128.24M
Cost of revenue 299.35M 196.90M 220.59M 155.50M 128.07M
Total other income expense net -4.50100M - -28.41400M -41.55700M 12.01M
Discontinued operations - - - - -
Net income from continuing ops -5.37400M - - - -
Net income applicable to common shares - 4.33M -16.83500M -29.89200M -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1046.30M 963.80M 945.49M 1054.84M 991.89M
Intangible assets 379.51M 283.61M 289.96M 338.78M 350.30M
Earning assets - - - - -
Other current assets 25.45M 0.00000M 20.63M 1.70M 4.51M
Total liab 279.03M 168.69M 198.62M 228.98M 149.87M
Total stockholder equity 767.27M 795.11M 746.87M 825.86M 842.02M
Deferred long term liab - - - - -
Other current liab 24.26M - 7.90M 15.01M 11.72M
Common stock 530.14M 534.27M 540.05M 599.05M 628.85M
Capital stock 530.14M - - 599.05M 628.85M
Retained earnings 148.94M 154.91M 150.89M 161.75M 191.65M
Other liab - - - - 31.89M
Good will 89.98M 86.48M 79.84M 82.27M 75.40M
Other assets - 28.46M - 15.60M 57.05M
Cash 76.45M 74.99M 58.76M 71.68M 85.96M
Cash and equivalents - 5.11M - 0.30M 9.03M
Total current liabilities 165.26M 111.25M 114.03M 141.32M 105.30M
Current deferred revenue - - 1.18M - -
Net debt 1.46M - 10.33M 6.02M -45.00500M
Short term debt 20.13M 0.00000M 19.58M 20.25M 28.28M
Short long term debt 16.73M - - 17.67M 26.66M
Short long term debt total 77.91M - 69.09M 77.70M 40.96M
Other stockholder equity 32.45M 79.99M 25.99M 23.78M 21.89M
Property plant equipment - 20.02M - 22.63M 29.94M
Total current assets 394.83M 396.81M 365.12M 395.62M 307.32M
Long term investments 79.48M - - 158.02M 178.95M
Net tangible assets - - - - 416.32M
Short term investments 18.83M 83.02M 95.66M 119.54M 77.03M
Net receivables 138.24M 105.20M 98.23M 110.20M 67.41M
Long term debt 51.16M 25.90M - 52.40M 9.27M
Inventory 135.87M 102.70M 91.83M 92.49M 72.40M
Accounts payable 120.87M - 85.37M 106.06M 65.31M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 55.74M - 29.95M 41.27M -0.37600M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8.88M - 7.77M 48.20M 47.93M
Deferred long term asset charges - - - - -
Non current assets total 651.46M - 580.38M 659.22M 684.57M
Capital lease obligations 10.02M - - 7.63M 5.03M
Long term debt total - 29.33M - 57.45M 12.68M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 50.99M - - - -
Change to liabilities - - - - -
Total cashflows from investing activities -84.10900M 16.96M 29.34M -63.07900M -
Net borrowings 20.52M - - - -
Total cash from financing activities 13.01M -33.54000M -71.12300M 1.76M -78.31000M
Change to operating activities - - - - -
Net income -5.37400M 4.33M -16.83500M -29.89200M 15.68M
Change in cash -3.65700M 21.34M -12.91800M -14.28400M -143.62900M
Begin period cash flow 80.11M - 71.68M 85.96M 229.59M
End period cash flow 76.45M - 58.76M 71.68M 85.96M
Total cash from operating activities 70.30M 36.28M 28.49M 40.48M 44.62M
Issuance of capital stock - - - - -
Depreciation 56.57M 53.11M 50.40M 62.62M 47.91M
Other cashflows from investing activities 17.60M 48.44M 39.30M -37.26300M -
Dividends paid 0.00000M - - - -
Change to inventory -17.82300M - 0.70M -11.42800M -17.18800M
Change to account receivables -26.53200M - 5.58M -26.41800M 8.59M
Sale purchase of stock -6.35200M -8.29000M -53.47900M -30.06900M -64.41500M
Other cashflows from financing activities -4.34100M -7.19900M -2.85100M 52.12M 9.72M
Change to netincome - - - - -
Capital expenditures 1.91M 31.47M 9.96M 25.82M 224.18M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.89M -19.62400M -28.01300M -9.98900M 0.63M
Stock based compensation 8.11M - 2.33M 1.89M 3.04M
Other non cash items 21.03M - 29.74M 32.98M -15.00800M
Free cash flow 68.40M - 18.54M 14.66M -179.56500M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GUD
Knight Therapeutics Inc.		 0.11 1.34% 8.31 - 48.54 1.64 0.96 1.60 11.97
CURA
Curaleaf Holdings Inc.		 -0.24 4.83% 4.73 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 -0.07 1.00% 6.90 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 -0.01 0.27% 3.76 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 -0.28 3.76% 7.16 - 1000.00 1.28 0.53 1.08 -2.299

Reports Covered

Stock Research & News

View All

Profile

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

Knight Therapeutics Inc.

100 Boul. Alexis-Nihon, Montreal, QC, Canada, H4M 2P2

Key Executives

Name Title Year Born
Mr. Jonathan Ross Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA Exec. Chairman 1969
Ms. Samira Sakhia BCom, CA, CPA, MBA Pres, CEO & Director 1968
Mr. Arvind Utchanah Chief Financial Officer NA
Ms. Amal Khouri B.Sc., M.B.A. Chief Bus. Officer NA
Mr. Jeff Martens Global VP Commercial NA
Mr. Leopoldo Bosano Vice-Pres of Manufacturing & Operations NA
Ms. Daniela Marino Global VP of Legal & Compliance NA
Ms. Susan Caroline Emblem Global VP of HR NA
Ms. Jody Engel Sr. Director of Bus. Devel. NA
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A. Executive Chairman 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.